<DOC>
	<DOCNO>NCT00612664</DOCNO>
	<brief_summary>The main purpose study estimate proportion patient type skin cancer call melanoma progression free , ( , cancer gotten substantially bad ) , treat Anti-CD137 ( 4-1BB ) ( BMS-663513 ) 0.1 mg/kg , 1 mg/kg 5 mg/kg every 3 week 1 mg/kg every 6 week</brief_summary>
	<brief_title>Phase II , 2nd Line Melanoma - RAND Monotherapy</brief_title>
	<detailed_description />
	<mesh_term>Melanoma</mesh_term>
	<criteria>Subjects must previously treat one line systemic anticancer therapy ( nonexperimental experimental ) metastatic disease , relapse , fail respond ( CR PR ) tolerate regimen . If treatment administer adjuvant and/or neoadjuvant therapy , subject must document disease progression last treatment also receive one additional line systemic therapy metastatic disease . Men woman , least 18 year age Ocular mucosal melanoma Complete surgical resection identifiable site disease Symptomatic brain metastasis . Subjects sign symptom suggestive brain metastasis eligible unless brain metastasis rule computerized axial tomography ( CT ) scan magnetic resonance imaging ( MRI ) . Subjects stable brain metastasis previously treat radiotherapy surgery must current evidence symptomatic brain metastasis steroid therapy least 4 week prior randomization</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2015</verification_date>
</DOC>